Short Spot Versus Long Lesion Stenting as Best Treatment for Extensive Occlusive SFA Disease (STRONG)
Primary Purpose
Peripheral Arterial Disease
Status
Terminated
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Short spot stenting
Long lesion stenting
Sponsored by
About this trial
This is an interventional treatment trial for Peripheral Arterial Disease
Eligibility Criteria
Inclusion Criteria:
- PAOD (ABI <0.90 and/or a decline of >0.15 after exercise test), Rutherford category 2, 3 or 4
- Multiple (>1) short (focal; >1 and < 5 cm) significant stenoses (≥ 50%) and/or occlusions in the superficial femoral artery
- Eligible for endovascular treatment via short spot stenting and via long lesion stenting according to international guidelines
- Unilateral occlusive disease
- Age ≥ 18
Exclusion Criteria:
- Patients with PAOD Rutherford category 5 and 6
- Impaired inflow due to significant lesions in the arteries proximal to the SFA intended to treat
- Bilateral lesions with treatment indication
- Contra-indication for anticoagulant therapy
- Renal insufficiency (MDRD < 50 ml/min)
- Life expectancy < 6 months
- Known contrast allergy
- Pregnancy
- Unable to complete a questionnaire in the home language
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
Short spot stenting
Long lesion stenting
Arm Description
Short spot stenting
Long lesion stenting
Outcomes
Primary Outcome Measures
absence of binary restenosis (≥ 50% re-obstruction) of the target lesion without interval clinically driven reintervention
Secondary Outcome Measures
Full Information
NCT ID
NCT03227822
First Posted
July 21, 2017
Last Updated
October 5, 2018
Sponsor
Catharina Ziekenhuis Eindhoven
1. Study Identification
Unique Protocol Identification Number
NCT03227822
Brief Title
Short Spot Versus Long Lesion Stenting as Best Treatment for Extensive Occlusive SFA Disease
Acronym
STRONG
Official Title
Short Spot Versus Long Lesion Stenting as Best Treatment for Extensive Occlusive SFA Disease; a Pilot Study
Study Type
Interventional
2. Study Status
Record Verification Date
October 2018
Overall Recruitment Status
Terminated
Why Stopped
Unable to include the number of patients
Study Start Date
July 2013 (undefined)
Primary Completion Date
February 1, 2015 (Actual)
Study Completion Date
February 1, 2015 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Catharina Ziekenhuis Eindhoven
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Since the length of lesion seems to be negatively associated with stent patency due to restenosis, it is thought that the efficacy of treatment in patients with multiple (> 1) short (focal; > 1 and < 5 cm) SFA lesions can be improved by spot stenting as compared to the use of one long stent. This study proposes to evaluate the endovascular treatment for patients with SFA lesions by comparing two strategies for patients with extensive occlusive SFA disease; 1) short spot (SS) stenting or 2) long lesion (LL) stenting.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Peripheral Arterial Disease
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
3 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Short spot stenting
Arm Type
Experimental
Arm Description
Short spot stenting
Arm Title
Long lesion stenting
Arm Type
Experimental
Arm Description
Long lesion stenting
Intervention Type
Procedure
Intervention Name(s)
Short spot stenting
Intervention Type
Procedure
Intervention Name(s)
Long lesion stenting
Primary Outcome Measure Information:
Title
absence of binary restenosis (≥ 50% re-obstruction) of the target lesion without interval clinically driven reintervention
Time Frame
1 year
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
PAOD (ABI <0.90 and/or a decline of >0.15 after exercise test), Rutherford category 2, 3 or 4
Multiple (>1) short (focal; >1 and < 5 cm) significant stenoses (≥ 50%) and/or occlusions in the superficial femoral artery
Eligible for endovascular treatment via short spot stenting and via long lesion stenting according to international guidelines
Unilateral occlusive disease
Age ≥ 18
Exclusion Criteria:
Patients with PAOD Rutherford category 5 and 6
Impaired inflow due to significant lesions in the arteries proximal to the SFA intended to treat
Bilateral lesions with treatment indication
Contra-indication for anticoagulant therapy
Renal insufficiency (MDRD < 50 ml/min)
Life expectancy < 6 months
Known contrast allergy
Pregnancy
Unable to complete a questionnaire in the home language
12. IPD Sharing Statement
Learn more about this trial
Short Spot Versus Long Lesion Stenting as Best Treatment for Extensive Occlusive SFA Disease
We'll reach out to this number within 24 hrs